USNA Usana Health Sciences Inc

Price (delayed)

$100.44

Market cap

$1.95B

P/E Ratio

15.2

Dividend/share

N/A

EPS

$6.61

Enterprise value

$1.71B

USANA prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative skincare line, USANA has proven for more than 25 ...

Highlights
The EPS has grown by 22% YoY
USNA's revenue is up by 12% year-on-year
The price to earnings (P/E) is 19% lower than the 5-year quarterly average of 18.7 but 3.4% higher than the last 4 quarters average of 14.7
USNA's net income is up by 17% year-on-year but it is down by 2.3% since the previous quarter
The quick ratio has contracted by 9% from the previous quarter and by 9% YoY

Key stats

What are the main financial stats of USNA
Market
Shares outstanding
19.46M
Market cap
$1.95B
Enterprise value
$1.71B
Valuations
Price to earnings (P/E)
15.2
Price to book (P/B)
5.04
Price to sales (P/S)
1.63
EV/EBIT
8.86
EV/EBITDA
7.95
EV/Sales
1.39
Earnings
Revenue
$1.23B
EBIT
$192.46M
EBITDA
$214.51M
Free cash flow
$133.15M
Per share
EPS
$6.61
Free cash flow per share
$6.67
Book value per share
$19.94
Revenue per share
$61.6
TBVPS
$26.61
Balance sheet
Total assets
$578.95M
Total liabilities
$179.87M
Debt
$0
Equity
$399.08M
Working capital
$210.46M
Liquidity
Debt to equity
0
Current ratio
2.33
Quick ratio
1.57
Net debt/EBITDA
-1.16
Margins
EBITDA margin
17.4%
Gross margin
81.8%
Net margin
11%
Operating margin
15.6%
Efficiency
Return on assets
22.7%
Return on equity
32.7%
Return on invested capital
156.9%
Return on capital employed
45.7%
Return on sales
15.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

USNA stock price

How has the Usana Health Sciences stock price performed over time
Intraday
0.44%
1 week
0.99%
1 month
-1.19%
1 year
29.35%
YTD
30.27%
QTD
8.94%

Financial performance

How have Usana Health Sciences's revenue and profit performed over time
Revenue
$1.23B
Gross profit
$1.01B
Operating income
$191.23M
Net income
$135.81M
Gross margin
81.8%
Net margin
11%
USNA's net income is up by 17% year-on-year but it is down by 2.3% since the previous quarter
The operating income has increased by 13% year-on-year but it has declined by 2.3% since the previous quarter
USNA's revenue is up by 12% year-on-year
The gross profit has increased by 12% year-on-year

Growth

What is Usana Health Sciences's growth rate over time

Valuation

What is Usana Health Sciences stock price valuation
P/E
15.2
P/B
5.04
P/S
1.63
EV/EBIT
8.86
EV/EBITDA
7.95
EV/Sales
1.39
The EPS has grown by 22% YoY
The price to earnings (P/E) is 19% lower than the 5-year quarterly average of 18.7 but 3.4% higher than the last 4 quarters average of 14.7
USNA's P/B is 10% above its last 4 quarters average of 4.6 and 2.9% above its 5-year quarterly average of 4.9
The company's equity fell by 4.7% QoQ but it rose by 2.6% YoY
USNA's revenue is up by 12% year-on-year
USNA's price to sales (P/S) is 4.1% less than its 5-year quarterly average of 1.7

Efficiency

How efficient is Usana Health Sciences business performance
The company's return on invested capital fell by 9% QoQ and by 8% YoY
The ROE has contracted by 3% from the previous quarter
Usana Health Sciences's ROA has decreased by 2.2% from the previous quarter

Dividends

What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for USNA.

Financial health

How did Usana Health Sciences financials performed over time
The quick ratio has contracted by 9% from the previous quarter and by 9% YoY
The current ratio has decreased by 6% from the previous quarter and by 2.9% YoY
USNA's debt is 100% less than its equity
The company's equity fell by 4.7% QoQ but it rose by 2.6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.